Latest updates & what is forthcoming

February 9, 2021

Here's what to look out for --

Previews of unpublished data undergoing peer review:

  • drug prophylaxis for COVID-19 (including hydroxychloroquine and ivermectin)

    • anticipated by mid-February

  • antibodies and cellular therapies for treatment of COVID-19 (including convalescent plasma and bamlanivimab)

    • ​anticipated by mid-February

  • updated data on drug treatments for COVID-19

    • anticipated by early March​


Peer-reviewed versions of the following:

  • adverse effects of remdesivir, hydroxychloroquine, and lopinavir/ritonavir

We're also studying the credibility of trial preprints during the COVID-19 pandemic. Stay tuned for our study protocol!

Send us a message here if you have any questions about what is forthcoming!